Asciminib in Combination with Imatinib, Nilotinib, or Dasatinib in Patients with Chronic Myeloid Leukemia in Chronic, or Accelerated Phase: Phase I Study Final Results

Asciminib, in combination with ATP-competitive tyrosine kinase inhibitors, demonstrated rapid efficacy offset by a decreased tolerability compared with asciminib monotherapy.